# Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke

Study · id `cardio:ct-nct06645522` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06645522](<https://clinicaltrials.gov/study/NCT06645522>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06645522

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT06645522. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-30 (anticipated); primary completion 2026-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT06645522, source copy `cardio:ctgov-nct06645522-2024-10-17`, retrieved 2026-10-26)
- Planned start: 2024-10-30 (anticipated) (ClinicalTrials.gov record NCT06645522, source copy `cardio:ctgov-nct06645522-2024-10-17`, retrieved 2026-10-26)
- Primary completion: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT06645522, source copy `cardio:ctgov-nct06645522-2024-10-17`, retrieved 2026-10-26)
- Completion: 2027-01-30 (anticipated) (ClinicalTrials.gov record NCT06645522, source copy `cardio:ctgov-nct06645522-2024-10-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06645522, source copy `cardio:ctgov-nct06645522-2024-10-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06645522-2024-10-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Edaravone dexborneol
- Intervention (Drug): Placebo
- Lead sponsor: Yi Yang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Yi Yang (`cardio:org-yi-yang`)

## Provenance

Content hash: 98d231e3ad174a1f96edc77266b342eab29ca47ec99c03840e631fab4ea023e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
